Semaglutide for Cardiovascular Disease
Verdict: Published with Warning
Across 5 PubMed studies, the evidence for Semaglutide in Cardiovascular Disease grades Tier A — moderate evidence. Effective, but with safety or population caveats.
A 🔵 A Moderate Evidence Published with Warning
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.72
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
A · Published with Warning
Confidence
87%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.722
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 negative 主導 (2 negative > 1 positive)，下層 RCT 不能推翻
- apply_hec_override — HEC-1 高階證據 negative — 強制由 A 改為 D
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (5)L2 · primary research & systematic reviews
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Finding: Pivotal SELECT trial: primary MACE 6.5% (semaglutide 2.4mg) vs 8.0% (placebo), HR 0.80 (95% CI 0.72-0.90, P<0.001), over mean 39.8-month follow-up.
View on PubMed Effect of semaglutide on mortality and cardiovascular events in patients at high cardiovascular risk: an updated systematic review and meta-analysis
Finding: Across 5 RCTs (n=37,267) MACE OR 0.81 (95% CI 0.76-0.87, P<0.001) and all-cause mortality OR 0.84 (95% CI 0.77-0.92, P<0.001); TSA confirmed MACE as conclusive but mortality had NOT reached the required information size.
View on PubMed Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials
Finding: 4 RCTs (n=27,617): MACE RR 0.81 (95% CI 0.74-0.88, P<0.001, I2=0%), driven by CV death and nonfatal MI, but NO significant effect on nonfatal stroke, heart-failure hospitalization, or unstable angina; discontinuation higher (RR 1.67).
View on PubMed Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease
Finding: 17 studies (n=40,632): CV death HR 0.77 (95% CI 0.68-0.88), MACE HR 0.82 (95% CI 0.75-0.90), nonfatal stroke HR 0.68 (95% CI 0.56-0.83); reductions most pronounced in T2D+CKD; no effect on eGFR/UACR.
View on PubMed Effects of oral semaglutide on cardiovascular outcomes: A systematic review and meta-analysis
Finding: 5 RCTs (n=13,875): cardiovascular events RR 0.86 (95% CI 0.78-0.95, p=0.0029); time-to-event HR 0.85 (95% CI 0.77-0.95), supporting oral-route CV benefit in T2D.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Supportive
The U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Wegovy is the first weight loss medication to also be app… source↗
L4b EU EFSA
Supportive
Wegovy: Authorised - This medicine is authorised for use in the European Union. Marketing authorisation date: 06 January 2022. The medicine can only be obtained with a prescription. Wegovy is used together with diet and physical activity to manage weight (including losing weight and keeping it off) in adults with a body mass index (BMI) of 30 kg/m2 or more (obesity) or in adults with a BMI of a… source↗
L4c UK NHS
Supportive
Semaglutide is recommended as an option for weight management, including weight loss and weight maintenance, alongside a reduced-calorie diet and increased physical activity in adults, only if: it is used for a maximum of 2 years, and within a specialist weight management service providing multidisciplinary management of overweight or obesity (including but not limited to tiers 3 and 4), and th… source↗
L4d TW TFDA / 衛福部
Supportive
胰妥讚 注射劑 Ozempic solution for injection 衛部菌疫輸字第001107 號；主成分 Semaglutide 1.34mg/mL,3mL；適應症：用於第二型糖尿病成人病人作為飲食和運動之輔助療法，以單一療法或與其他糖尿病治療藥品併用方式，治療控制不佳之第二型糖尿病；對於第二型糖尿病合併已確診心血管疾病之病人，可降低主要不良心血管事件之風險。健保給付規定：限第二型糖尿病病人經 metformin 及/或 sulfonylurea 兩類藥品最大耐受劑量，及繼續使用下列藥品其中之一達 6 個月後 HbA1c 仍 ≥8.5% 者使用。 source↗
L4e WHO
Supportive
GLP-1 therapies may be used by adults, but excluding pregnant women, for the long-term treatment of obesity. [...] GLP-1 receptor agonists – semaglutide, dulaglutide and liraglutide [added to EML] for adults with type 2 diabetes mellitus with established cardiovascular disease or chronic kidney disease and obesity (defined as body mass index (BMI) ≥ 30kg/m2). [...] High prices of medicines like… source↗
L5a NIH Office of Dietary Supplements
Supportive
Semaglutide (Ozempic, Wegovy, Rybelsus) is a prescription GLP-1 medication used for weight loss and weight management, type 2 diabetes treatment, or to reduce the risk of chronic kidney disease and major cardiovascular events in certain patients with type 2 diabetes. Semaglutide (Wegovy) is also used to treat metabolic dysfunction-associated steatohepatitis (MASH), without cirrhosis of the live… source↗
L5b Mayo Clinic
Supportive
Semaglutide is used to lower the risk of heart attack, stroke, or death in patients with type 2 diabetes who are at high risk for these events. It is also used to lower the risk of heart attack, stroke, or death in patients with type 2 diabetes, obesity, and heart or blood vessel disease. Studies have found that semaglutide reduces the risk of major cardiovascular events, including heart attack… source↗
L5c Cleveland Clinic
Supportive
In the trial, for patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly injections of semaglutide at a dose of 2.4 mg was superior to placebo in reducing the risk of death from cardiovascular causes, nonfatal heart attack, or nonfatal stroke over an average follow-up of 40 months. Death from a cardiovascular event, nonfatal myocardial infarction… source↗
L5d Harvard Health
Supportive
those who took semaglutide were 20% less likely to have a heart attack or stroke or to die from heart-related causes. The NEJM study compared a 2.4-milligram dose of semaglutide (the highest dose of Wegovy) to a placebo in more than 17,000 people with cardiovascular disease. People taking semaglutide lost an average of nearly 19 pounds, which probably explains why their blood pressure, triglyce… source↗
L5e Specialty Society (condition-mapped)
Supportive
There was a 20% reduction in the risk of heart attacks, strokes or death due to cardiovascular disease in the participants who took semaglutide, compared to the participants in the placebo group. This news is very encouraging for people with overweight or obesity because no treatment specifically directed at the management of obesity and overweight in people without Type 1 or Type 2 diabetes ha… source↗